Dr. Reddys Laboratories is currently trading at Rs. 2600.30, up by 7.00 points or 0.27% from its previous closing of Rs. 2593.30 on the BSE.
The scrip opened at Rs. 2612.00 and has touched a high and low of Rs. 2612.00 and Rs. 2585.55 respectively. So far 6,721 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2560.00 on 22-Mar-2017.
Last one week high and low of the scrip stood at Rs. 2651.40 and Rs. 2585.55 respectively. The current market cap of the company is Rs. 43,025.00 crore.
The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.
Dr. Reddys Laboratories has launched Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg a therapeutic equivalent generic version of Vytorin (Ezetimibe and Simvastatin) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's is among the first companies to launch the generic product in the U.S. market.
The Vytorin brand had U.S. sales of approximately $678 million MAT for the most recent twelve months ended in February 2017 according to IMS Health. Dr. Reddy's Ezetimibe and Simvastatin Tablets are available in bottle count sizes of 30, 90 and 1000. Vytorin is a registered trademark of MSD International GmbH.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |